Charles Hart, PhD

Title(s)Director Catalyst Program, Innovation Ventures
SchoolChancellor/EVC/FAS
Address600 16th St
San Francisco CA 94158
Phone415-514-8510
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide. Mol Pharmacol. 2019 06; 95(6):638-651. Hunter FW, Devaux JBL, Meng F, Hong CR, Khan A, Tsai P, Ketela TW, Sharma I, Kakadia PM, Marastoni S, Shalev Z, Hickey AJR, Print CG, Bohlander SK, Hart CP, Wouters BG, Wilson WR. PMID: 30979813.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    2. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCI Insight. 2018 08 23; 3(16). Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW. PMID: 30135316.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    3. Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study. Neuro Oncol. 2018 08 02; 20(9):1231-1239. Brenner A, Zuniga R, Sun JD, Floyd J, Hart CP, Kroll S, Fichtel L, Cavazos D, Caflisch L, Gruslova A, Huang S, Liu Y, Lodi A, Tiziani S. PMID: 29415215.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    4. Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice. Cancer Res. 2018 07 15; 78(14):3783-3792. Matsumoto S, Kishimoto S, Saito K, Takakusagi Y, Munasinghe JP, Devasahayam N, Hart CP, Gillies RJ, Mitchell JB, Krishna MC. PMID: 29792309.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    5. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies. Antioxid Redox Signal. 2018 Jan 10; 28(2):131-140. Takakusagi Y, Kishimoto S, Naz S, Matsumoto S, Saito K, Hart CP, Mitchell JB, Krishna MC. PMID: 28741367.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    6. A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model. Transl Oncol. 2017 Oct; 10(5):760-765. Hajj C, Russell J, Hart CP, Goodman KA, Lowery MA, Haimovitz-Friedman A, Deasy JO, Humm JL. PMID: 28778024.
      View in: PubMed   Mentions:
    7. Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models. Tomography. 2016 Sep; 2(3):229-237. Stokes AM, Hart CP, Quarles CC. PMID: 27752544.
      View in: PubMed   Mentions: 11     Fields:    
    8. Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. Clin Cancer Res. 2017 Jan 15; 23(2):536-548. Duran R, Mirpour S, Pekurovsky V, Ganapathy-Kanniappan S, Brayton CF, Cornish TC, Gorodetski B, Reyes J, Chapiro J, Schernthaner RE, Frangakis C, Lin M, Sun JD, Hart CP, Geschwind JF. PMID: 27440271.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    9. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1a inhibition, and hypoxia-activated chemotherapy. Oncotarget. 2016 Jul 12; 7(28):42844-42858. Yoon C, Chang KK, Lee JH, Tap WD, Hart CP, Simon MC, Yoon SS. PMID: 27374091.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    10. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One. 2016; 11(5):e0155289. Zhang X, Wojtkowiak JW, Martinez GV, Cornnell HH, Hart CP, Baker AF, Gillies R. PMID: 27227903.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    11. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models. . 2016 04 02; 17(4):371-80. Sun JD, Liu Q, Ahluwalia D, Ferraro DJ, Wang Y, Jung D, Matteucci MD, Hart CP. PMID: 26818215.
      View in: PubMed   Mentions:
    12. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res. 2016 Apr 01; 22(7):1687-98. Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P, Jacamo R, Ma H, Konoplev S, McQueen T, Volgin A, Protopopova M, Mu H, Lee J, Bhattacharya PK, Marszalek JR, Davis RE, Bankson JA, Cortes JE, Hart CP, Andreeff M, Konopleva M. PMID: 26603259.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    13. Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models. Am J Cancer Res. 2015; 5(7):2139-55. Sun JD, Ahluwalia D, Liu Q, Li W, Wang Y, Meng F, Bhupathi D, Matteucci MD, Hart CP. PMID: 26328245.
      View in: PubMed   Mentions:
    14. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21; 15:422. Meng F, Bhupathi D, Sun JD, Liu Q, Ahluwalia D, Wang Y, Matteucci MD, Hart CP. PMID: 25994202.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    15. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. Clin Cancer Res. 2015 Jul 01; 21(13):2984-92. Peeters SG, Zegers CM, Biemans R, Lieuwes NG, van Stiphout RG, Yaromina A, Sun JD, Hart CP, Windhorst AD, van Elmpt W, Dubois LJ, Lambin P. PMID: 25805800.
      View in: PubMed   Mentions: 37     Fields:    Translation:Animals
    16. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. . 2015; 16(3):438-49. Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, Bhupathi D, Ruprell AS, Hart CP. PMID: 25679067.
      View in: PubMed   Mentions:
    17. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer. PLoS One. 2014; 9(12):e113586. Bailey KM, Cornnell HH, Ibrahim-Hashim A, Wojtkowiak JW, Hart CP, Zhang X, Leos R, Martinez GV, Baker AF, Gillies RJ. PMID: 25532146.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    18. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302. PLoS One. 2014; 9(9):e107995. Takakusagi Y, Matsumoto S, Saito K, Matsuo M, Kishimoto S, Wojtkowiak JW, DeGraff W, Kesarwala AH, Choudhuri R, Devasahayam N, Subramanian S, Munasinghe JP, Gillies RJ, Mitchell JB, Hart CP, Krishna MC. PMID: 25254649.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    19. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models. Clin Cancer Res. 2013 Dec 01; 19(23):6506-19. Portwood S, Lal D, Hsu YC, Vargas R, Johnson MK, Wetzler M, Hart CP, Wang ES. PMID: 24088735.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    20. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. . 2013 Sep; 12(9):1763-73. Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, De Bryune E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K. PMID: 23832122.
      View in: PubMed   Mentions:
    21. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012 Jun 14; 119(24):5782-94. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM. PMID: 22394600.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansAnimalsCells
    22. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1487-98. Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. PMID: 22382881.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansAnimalsCells
    23. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res. 2012 Feb 01; 18(3):758-70. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. PMID: 22184053.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansAnimalsCells
    24. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. . 2012 Mar; 11(3):740-51. Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP. PMID: 22147748.
      View in: PubMed   Mentions:
    25. 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment. J Med Chem. 2011 Mar 24; 54(6):1715-23. Duan JX, Cai X, Meng F, Sun JD, Liu Q, Jung D, Jiao H, Matteucci J, Jung B, Bhupathi D, Ahluwalia D, Huang H, Hart CP, Matteucci M. PMID: 21341674.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    26. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood. 2010 Sep 02; 116(9):1524-7. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K. PMID: 20530289.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsCells
    27. Geochemistry of inorganic nitrogen in waters released from coal-bed natural gas production wells in the Powder River Basin, Wyoming. Environ Sci Technol. 2009 Apr 01; 43(7):2348-54. Smith RL, Repert DA, Hart CP. PMID: 19452885.
      View in: PubMed   Mentions:    Fields:    
    28. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem. 2008 Apr 24; 51(8):2412-20. Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M. PMID: 18257544.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCells
    29. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. Cancer Chemother Pharmacol. 2008 May; 61(6):953-63. Meng F, Cai X, Duan J, Matteucci MG, Hart CP. PMID: 17639393.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    30. ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation. Anticancer Drugs. 2007 Apr; 18(4):435-45. Meng F, Nguyen XT, Cai X, Duan J, Matteucci M, Hart CP. PMID: 17351396.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    31. Finding the target after screening the phenotype. Drug Discov Today. 2005 Apr 01; 10(7):513-9. Hart CP. PMID: 15809197.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    Charles's Networks
    Concepts (205)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.0.0-839-g49dc76ac on PROFILES-PWEB01.

    Copyright © The Regents of the University of California